Vergelijking

Buserelin vs. Icatibant

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

57982-77-1

138614-30-9

Molecuulmassa

1239.42 g/mol

1304.52 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Buserelin	Icatibant
Duitsland	Op recept	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Buserelin

Volledige vermelding →

Icatibant

Volledige vermelding →

Frequently asked questions

What is the difference between Buserelin and Icatibant?: Buserelin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Icatibant?: The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Icatibant in Germany and the United States?: Duitsland: Buserelin — Op recept, Icatibant — Op recept. Verenigde Staten: Buserelin — Niet goedgekeurd, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Icatibant

Duitsland

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Buserelin and Icatibant?

Buserelin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Icatibant?

The highest available evidence level is "Humane RCT" for Buserelin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Icatibant in Germany and the United States?

Duitsland: Buserelin — Op recept, Icatibant — Op recept. Verenigde Staten: Buserelin — Niet goedgekeurd, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.